- Home
- NBIX
as 10-07-2025 3:29pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 14.4B | IPO Year: | 1996 |
| Target Price: | $163.71 | AVG Volume (30 days): | 895.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.39 | EPS Growth: | 2.97 |
| 52 Week Low/High: | $84.23 - $154.61 | Next Earning Date: | 10-29-2025 |
| Revenue: | $2,509,900,000 | Revenue Growth: | 18.42% |
| Revenue Growth (this year): | 20.75% | Revenue Growth (next year): | 14.73% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | N/A | Aug 7 '25 | Sell | $126.41 | 106,322 | $13,440,280.97 | 514,596 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
MT Newswires
15 days ago
Neurocrine Biosciences Says Ingrezza Shows Earlier Remission of Tardive Dyskinesia Symptoms
PR Newswire
15 days ago
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
PR Newswire
16 days ago
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Simply Wall St.
19 days ago
Exploring High Growth Tech Stocks In The US Market September 2025
PR Newswire
21 days ago
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Insider Monkey
21 days ago
What Does Wall Street Think About Neurocrine Biosciences (NBIX)?
MT Newswires
a month ago
RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.